We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Emergent Biosolutions Inc | NYSE:EBS | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.665 | 13.09% | 5.745 | 5.85 | 5.1507 | 5.27 | 2,322,687 | 18:54:03 |
By Chris Wack
Emergent BioSolutions shares were up 16% to $8.22 in premarket trading after the company said late Thursday that the U.S. Food and Drug Administration has approved Cyfendus for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years old.
The stock hit its 52-week low of $6.77 on July 6, and is down 78% as of Thursday's close.
The company said the efficacy of the Cyfendus vaccine for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax.
Emergent BioSolutions said Cyfendus has been demonstrated that by using an additional adjuvant, two doses administered over 14 days elicit protective levels of immune response, which can be especially important in response to a large-scale public health emergency involving anthrax.
In December 2018, Cyfendus was the subject of a pre-emergency use authorization package submitted to the FDA. In 2019, the U.S. government began procuring this product for national preparedness efforts.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 21, 2023 06:59 ET (10:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Emergent Biosolutions Chart |
1 Month Emergent Biosolutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions